JP2022535816A5 - - Google Patents

Info

Publication number
JP2022535816A5
JP2022535816A5 JP2021571671A JP2021571671A JP2022535816A5 JP 2022535816 A5 JP2022535816 A5 JP 2022535816A5 JP 2021571671 A JP2021571671 A JP 2021571671A JP 2021571671 A JP2021571671 A JP 2021571671A JP 2022535816 A5 JP2022535816 A5 JP 2022535816A5
Authority
JP
Japan
Application number
JP2021571671A
Other languages
Japanese (ja)
Other versions
JP7680375B2 (ja
JPWO2020247974A5 (https=
JP2022535816A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/070113 external-priority patent/WO2020247974A1/en
Publication of JP2022535816A publication Critical patent/JP2022535816A/ja
Publication of JP2022535816A5 publication Critical patent/JP2022535816A5/ja
Publication of JPWO2020247974A5 publication Critical patent/JPWO2020247974A5/ja
Priority to JP2025077691A priority Critical patent/JP2025121986A/ja
Application granted granted Critical
Publication of JP7680375B2 publication Critical patent/JP7680375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571671A 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 Active JP7680375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077691A JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856468P 2019-06-03 2019-06-03
US62/856,468 2019-06-03
PCT/US2020/070113 WO2020247974A1 (en) 2019-06-03 2020-06-03 Methods and compositions for treating cancer with collagen binding drug carriers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077691A Division JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Publications (4)

Publication Number Publication Date
JP2022535816A JP2022535816A (ja) 2022-08-10
JP2022535816A5 true JP2022535816A5 (https=) 2023-06-13
JPWO2020247974A5 JPWO2020247974A5 (https=) 2023-06-13
JP7680375B2 JP7680375B2 (ja) 2025-05-20

Family

ID=73652058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571671A Active JP7680375B2 (ja) 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
JP2025077691A Pending JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077691A Pending JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Country Status (9)

Country Link
US (1) US20220298225A1 (https=)
EP (1) EP3976111A4 (https=)
JP (2) JP7680375B2 (https=)
CN (1) CN114173822B (https=)
AU (1) AU2020289485A1 (https=)
BR (1) BR112021024438A2 (https=)
CA (1) CA3144535A1 (https=)
MX (1) MX2021014932A (https=)
WO (1) WO2020247974A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024177006A1 (https=) * 2023-02-20 2024-08-29
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド 免疫療法のctla−4結合ペプチド
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
KR101808751B1 (ko) * 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(vWF)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
JP6508785B2 (ja) * 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
WO2016033331A1 (en) * 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
WO2016054107A1 (en) * 2014-09-29 2016-04-07 Counterpoint Biomedica Llc Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
AU2019366956B2 (en) * 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2022535816A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)